Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | CTSV | O60911 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | CTSC | P53634 | 1/20 | 0.44 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | CDC25B | P30305 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7524909 | 1.00 | LMNA (0.48) | LMNAAKT1BCHEACHECTSV | |
| SCHEMBL21218218 | 0.91 | BCHE (0.50) | LMNAAKT1BCHEACHECTSV | |
| SCHEMBL21283176 | 0.91 | BCHE (0.50) | LMNAAKT1BCHEACHECTSV | |
| SCHEMBL19223109 | 0.91 | BCHE (0.50) | LMNAAKT1BCHEACHECTSV | |
| SCHEMBL9838697 | 0.91 | BCHE (0.50) | LMNAAKT1BCHEACHECTSV | |
| SCHEMBL24725534 | 0.91 | BCHE (0.50) | LMNAAKT1BCHEACHECTSV | |
| SCHEMBL14429283 | 0.83 | BCHE (0.48) | LMNAAKT1BCHEACHECTSV | |
| SCHEMBL20654338 | 0.81 | AKT1 (0.51) | LMNAAKT1BCHEACHEPTPN1 | |
| SCHEMBL7154872 | 0.80 | LMNA (0.48) | LMNAAKT1BCHEACHECTSV | |
| SCHEMBL3142790 | 0.79 | LMNA (0.63) | LMNAAKT1BCHEACHEPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4023650-A1 | 4'-SUBSTITUTED-FURO[3,2-D]PYRIMIDINE AND -PYRROLO[3,2- D]PYRIMIDINE DERIVATIVES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20220185832-A1 | CD73 INHIBITORS | BIOARDIS LLC | 2022-06-16 | — | — | US | disclosed |
| EP-3785717-B1 | METHODS FOR TREATING CORONAVIRIDAE INFECTIONS | GILEAD SCIENCES INC (US) | 2022-01-05 | — | — | EP | disclosed |
| EP-3212175-B1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES INC (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020157694-A9 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | Janssen Biopharma, Inc. (US) | 2021-11-11 | — | — | WO | disclosed |
| EP-3785717-A1 | METHODS FOR TREATING CORONAVIRIDAE INFECTIONS | Gilead Sciences, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-3695844-A1 | METHODS FOR TREATING NIPAH VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2020157694-A1 | ANTIVIRAL NUCLEOSIDES AND DERIVATIVES THEREOF | Janssen Biopharma, Inc. (US) | 2020-08-06 | — | — | WO | disclosed |
| EP-3174870-B1 | THIENO [3,2-D]PYRIMIDINES, FURO [3,2,D]PYRIMIDINES AND PYRROLO [3,2-D]PYRIMIDINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3068405-B1 | PYRROLO [1,2,F][1,2,4]TRIAZINES USEFUL FOR TREATING RESPIRATORY SYNCITIAL VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2019-05-01 | — | — | EP | disclosed |
| EP-3212174-B1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-2719701-B1 | Method for the preparation of thieno[3,4-d]pyrimidin-7-yl ribosides | GILEAD SCIENCES INC (US) | 2017-04-05 | — | — | EP | disclosed |
| WO-2011035250-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-6448415-B1 | Chirality conversion method in lactone sugar compounds | HANCHEM CO., LTD. (KR) | 2002-09-10 | — | — | US | disclosed |
| US-20020028955-A1 | Chirality conversion method in lactone sugar compounds | HANCHEM CO., LTD. (KR) | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028955-A1 | Chirality conversion method in lactone sugar compounds | TREH, FUT6, TALDO1 | LMNA 1562/4885AKT1 608/4885BCHE 798/4885 |
| US-20220185832-A1 | CD73 INHIBITORS | ENTPD5, ENTPD1, ENTPD2 | LMNA 2492/4885AKT1 1156/4885BCHE 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.